NCT05194293进行中（未招募）2 期
Neoadjuvant Regorafenib Plus Durvalumab (MEDI4736) in Patients With High-Risk Hepatocellular Carcinoma
Academic and Community Cancer Research United5 个研究点 分布在 1 个国家目标入组 4 人开始时间: 2023年7月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 4
- 试验地点
- 5
- 主要终点
- Objective response rate (ORR) (unconfirmed)
研究概览
简要总结
This phase II trial tests whether regorafenib and durvalumab work to shrink tumors in patients with high-risk liver cancer. Regorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving regorafenib and durvalumab may work better in treating patients with high-risk liver cancer.
详细描述
PRIMARY OBJECTIVE:
I. To assess the overall response rate (ORR) at 16 weeks post registration.
SECONDARY OBJECTIVES:
I. To assess the rate of patients who undergo surgery during the course of the study.
II. To assess the safety and tolerability of the combination therapy of regorafenib plus durvalumab.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age >= 18 years at time of study entry
- •Body weight > 30 kg
- •Patients must have hepatocellular carcinoma (HCC) diagnosis confirmed by histology/cytology or clinically by American Association for Study of liver Diseases (AASLD) criteria in cirrhotic patients
- •Measurable disease
- •Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
- •Child Pugh class A
- •Total bilirubin =< 1.5 x upper limit of normal (ULN) (obtained =< 28 days prior to registration)
- •Alanine aminotransferase (ALT) =< 5 x ULN (obtained =< 28 days prior to registration)
- •Aspartate transaminase (AST) =< 5 x ULN (obtained =< 28 days prior to registration)
- •Prothrombin time (PT)/international normalized ratio (INR)/activated partial thromboplastin time (aPTT) =< 1.5 x ULN OR if patient is receiving anticoagulant therapy and INR or aPTT is within target range of therapy (obtained =< 28 days prior to registration)
- •Creatinine =< 1.5 x ULN or creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels > 1.5 x ULN. Creatinine clearance should be calculated per institutional standard (obtained =< 28 days prior to registration)
- •Urinary protein is =< 1+ on dipstick or routine urinalysis or 24-hour urine demonstrating < 1 gram of protein (obtained =< 28 days prior to registration)
- •Absolute neutrophil count (ANC) >= 1.0 x 10^9/Liter (obtained =< 28 days prior to registration)
- •Hemoglobin >= 9 grams/deciliter (obtained =< 28 days prior to registration)
- •Platelets >= 75 x 10^9/Liter (obtained =< 28 days prior to registration)
- •Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
- •Life expectancy of >= 12 weeks
- •Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
- •NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
- •Provide informed written consent =< 28 days prior to registration
- •Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
- •Note: During the active monitoring phase of a study (i.e., active treatment and clinical follow-up), participants must be willing to return to the consenting institution for follow-up
- •Willing to provide mandatory tissue specimens and/or blood specimens for correlative research purposes
- •Clinical staging T1b/T2 or T3 hepatocellular cancer TNM staging American Joint Committee on Cancer (AJCC) International Union Against Cancer (UICC) 8th edition
- •Solitary tumor > 5 cm without vascular invasion
- •T2: Solitary tumor > 2 cm with vascular invasion, or multiple tumors, none > 5 cm
- •T3: Multiple tumors, at least one of which is > 5 cm
- •Able to swallow oral medication
排除标准
- •Prior therapy with anti-PD-1, PD L-1 antibody including durvalumab, regorafenib, or other approved systemic therapies for HCC
- •Mixed histology HCC or fibrolamellar HCC
- •History of upper gastrointestinal bleed =< 6 months from registration
- •Liver directed therapy =< 28 days prior to registration. Prior liver directed therapy > 28 days prior to registration is allowed
- •Evidence of extrahepatic metastatic disease
- •Suitable for liver transplant
- •Participation in another clinical study where the patient has received any dose of an investigational product =< 90 days prior to registration
- •Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study
- •Any unresolved toxicity National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade >= 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria
- •Patients with grade >= 2 neuropathy will be evaluated on a case-by-case basis after consultation with the study physician
- •Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the study physician
- •Any concurrent chemotherapy, investigational product (IP), biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable
- •Major surgical procedure (as defined by the investigator) =< 28 days prior to registration
- •History of allogenic organ transplantation
- •Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:
- •Patients with vitiligo or alopecia
- •Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
- •Any chronic skin condition that does not require systemic therapy
- •Patients without active disease in the last 5 years may be included but only after consultation with the study physician
- •Patients with celiac disease controlled by diet alone
- •Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring adverse events (AEs) or compromise the ability of the patient to give written informed consent
- •History of another primary malignancy except for
- •Malignancy treated with curative intent and with no known active disease >= 3 years before registration and of low potential risk for recurrence
- •Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
- •Adequately treated carcinoma in situ without evidence of disease
- •History of leptomeningeal carcinomatosis
- •Single 12 Lead electrocardiogram (ECG) which Fridericia's correction formula (QTcF) > 470 ms
- •NOTE: In case of clinically significant ECG abnormalities, including a QTcF value > 470 ms, 2 additional 12-lead ECGs should be obtained over a brief period (within 30 minutes) to confirm the finding
- •Immunocompromised and known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy
- •Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis (TB) testing in line with local practice), hepatitis B (known positive hepatitis B virus [HBV] surface antigen [HBsAg] result), hepatitis C. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA)
- •Current or prior use of immunosuppressive medication =< 14 days prior to registration. The following are exceptions to this criterion:
- •Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)
- •Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
- •Steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication)
- •Receipt of live attenuated vaccine =< 30 days prior to registration. Note: Patients, if enrolled, should not receive live vaccine whilst receiving investigational product (IP) and up to 30 days after the last dose of durvalumab and regorafenib
- •Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy
- •Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients
- •Prior randomization or treatment in a previous durvalumab clinical study regardless of treatment arm assignment
研究组 & 干预措施
Treatment (regorafenib, durvalumab)
Experimental
Patients receive regorafenib PO QD on days 1-21 and durvalumab IV on day 1. Treatment repeats every 28 days for a maximum of 2 years from registration or until decision to proceed to surgery, disease progression, excessive toxicity, or patient withdrawal.
干预措施: Durvalumab (Biological)
Treatment (regorafenib, durvalumab)
Experimental
Patients receive regorafenib PO QD on days 1-21 and durvalumab IV on day 1. Treatment repeats every 28 days for a maximum of 2 years from registration or until decision to proceed to surgery, disease progression, excessive toxicity, or patient withdrawal.
干预措施: Regorafenib (Drug)
结局指标
主要结局
Objective response rate (ORR) (unconfirmed)
时间窗: At 16 weeks
An objective response is defined as a complete response (CR) or partial response (PR). Disease status will be assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version (v).1.1 criteria. ORR is defined as the proportion of evaluable patient who experience a CR or PR divided by the total number of evaluable patients. The final ORR point estimate and corresponding 95% confidence interval will be reported.
Objective Response Rate (ORR) (Unconfirmed)
时间窗: 16 weeks
An objective response is defined as a complete response (CR) or partial response (PR). Disease status will be assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version (v).1.1 criteria. ORR is defined as the proportion of evaluable patient who experience a CR or PR divided by the total number of evaluable patients. The final ORR point estimate and corresponding 95% confidence interval will be reported.
次要结局
- Rate of surgery during the course of the study(Up to 10 months)
- Incidence of adverse events(Up to 3 years)
- Progression-free survival (PFS)(3 years)
- Overall survival (OS)(3 years)
- Recurrence-free survival (RFS)(3 years)
- Pathologic complete response(Up to 10 months)
- Rate of Surgery During the Course of the Study(10 months)
- Number of Patients Experiencing Adverse Events(2 years)
- Progression-free Survival (PFS)(2 years)
- Overall Survival (OS)(2 years)
- Recurrence-free Survival (RFS)(2 years)
- Pathologic Complete Response Rate(10 months)
研究者
研究点 (5)
Loading locations...
相似试验
进行中（未招募）
1 期
The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract CancersAdvanced Biliary Tract CancerNCT04781192University of Kansas Medical Center40
终止
2 期
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + BevacizumabBCLC Stage B Hepatocellular CarcinomaBCLC Stage C Hepatocellular CarcinomaLocally Advanced Hepatocellular CarcinomaMetastatic Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v8Stage IIIA Hepatocellular Carcinoma AJCC v8Stage IIIB Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8Stage IVA Hepatocellular Carcinoma AJCC v8Stage IVB Hepatocellular Carcinoma AJCC v8Unresectable Hepatocellular CarcinomaNCT05199285Academic and Community Cancer Research United15
招募中
2 期
Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA TrialColorectal Cancer Stage IVNo Evidence of Disease StateNCT05382741Ospedale Policlinico San Martino182
进行中（未招募）
2 期
Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung CancerPlatinum-Resistant Lung Small Cell CarcinomaPlatinum-Sensitive Lung Small Cell CarcinomaRecurrent Extensive Stage Lung Small Cell CarcinomaRefractory Extensive Stage Lung Small Cell CarcinomaNCT04607954Mayo Clinic29
已完成
2 期
Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube CancerPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaRefractory Fallopian Tube CarcinomaRefractory Ovarian CarcinomaRefractory Primary Peritoneal CarcinomaNCT03026062M.D. Anderson Cancer Center100